In this video interview, Sam Hinsley, statistics manager at Phastar, introduces the Early Phase ESIG, a new special interest ...
In a recent video interview with Applied Clinical Trials, Abraham Gutman, founder and CEO of AG Mednet, discussed the concept ...
Across 42 coordinators (mean 6.2 years’ experience), only 45% of problems were identified on average, indicating substantial ...
In this video interview, Sam Hinsley, statistics manager at Phastar, explains why early phase decisions are the foundation of the entire development pathway and what is at stake statistically when ...
In a new video interview, Abraham Gutman, founder and CEO of AG Mednet, explained why data capture advances have not addressed the underlying execution problem in clinical trials and what a practical ...
In this Q&A, Del Smith, PhD, CEO and co-founder of Acclinate, discusses how structural and relational barriers continue to limit participation from underrepresented communities in clinical trials—and ...
In this video interview, Abraham Gutman, founder and CEO of AG Mednet, describes how AI can take on rote reasoning tasks like PHI redaction and document QA, and why offloading that work is what gives ...
Vendor capability gaps and failed implementations erode sponsor trust, while complex neurocognitive instruments can be ...
In this Q&A, Adrelia Allen, executive director of clinical trial patient diversity at Merck, discusses how the company is embedding diversity into clinical trial execution—from protocol design and ...
In today's ACT Brief, we examine how Merck embeds diversity into trial execution from design through community engagement, a new statistician special interest group for early phase research, and FDA's ...
Shareholder votes in 2025 uniformly rejected anti-DEI proposals, while many sponsors rebrand DEI under culture, belonging, and performance rather than dismantling commitments. Heightened DOJ/EEOC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results